Report ID: 10325506 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Global Diabetic Nephropathy Market is estimated to reach $3,826 million by 2024; growing at a CAGR of 5.9% from 2016 to 2024. Diabetic nephropathy involves damage of kidney due to the presence of diabetic mellitus. It is a progressive kidney disease majorly caused due to occurrence if persistent proteinuria in diabetic patients. It affects people suffering from type1 and type2 diabetes. Diabetic nephropathy comprises of 5 stages, with the final being end-stage renal disease (ESRD). Patient affected by diabetic nephropathy shows symptoms of weakness, vomiting, leg swelling, high blood pressure, nausea, high albumin secretion in urine, and high level of blood urea nitrogen. Diabetic nephropathy affects around 40% of people suffering from type1 and type2 diabetics. Moreover, it is also capable of increases the chances of cardiovascular mortality. Regular awareness programs are being initiated by various government and NGOs which aids in inculcating the knowledge of preventive measures and treatments among diabetes population.
The global diabetic nephropathy market is driven by rising obesity and diabetes among population, rise in number of people suffering from kidney diseases, growing awareness and rising investments in research and development. Though, longer duration for drug approvals and government regulations may limit the growth in forecasted period. Additionally, rising awareness and demand for combination therapies might provide opportunities for the market.
The global diabetic nephropathy market is classified into mode of treatment and geography. Mode of treatment is bifurcated into drug modifying therapies (renin inhibitors, connective tissue growth factor inhibitor (CTGF), angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blockers (ARBs), monocyte chemoattractant proteins (MCP) inhibitors, diuretics, G protein-coupled receptors (GPCRs), calcium channel blockers (CCBs), antioxidant inflammation modulator (AIM), endothelin-A receptors antagonist (ETAR), and others) and others.
By geography, the market has been bifurcated into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The U.S., Canada, Mexico are covered under North America wherein Europe covers UK, Germany, France Italy, and others. Asia-Pacific covers China, Japan, India, South Korea, and others. RoW covers South America, Middle East, and Africa.
Key players in the market include Mallinckrodt Pharmaceuticals, Bayer AG, Mitsubishi Tanabe Pharma Corporation, GenKyoTex S.A., Novartis AG, Eli Lilly and Company, Mesoblast Ltd., Ampio Pharmaceuticals Inc., Reata Pharmaceuticals, and ChemoCentryx Inc., among others.
The key takeaways from the report:
The report will provide a detailed analysis of Global Diabetic Nephropathy Market with respect to major segments such as mode of treatment and geography
The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024
Comprehensive analysis of market dynamics including factors and opportunities will be provided in the report
An exhaustive regional analysis of Global Diabetic Nephropathy s Market from 2015 to 2024 will be included in the report
Profile of the key players in the Global Diabetic Nephropathy Market will be provided, which include key financials, product & services, new developments and business strategies
Scope of the Global Diabetic Nephropathy Market:
Mode of Treatment Segments
Drug Modifying Therapies
Renin Inhibitors
Connective Tissue Growth Factor Inhibitor (CTGF)
Angiotensin-Converting Enzyme (ACE) Inhibitor
Angiotensin Receptor Blockers (ARBs)
Monocyte Chemoattractant Proteins (MCP) Inhibitors
Diuretics
G Protein-Coupled Receptors (GPCRs)
Calcium Channel Blockers (CCBs)
Antioxidant Inflammation Modulator (AIM)
Endothelin-A Receptors Antagonist (ETAR)
Other Drug Modifying Therapies
Other Mode of Treatments
Geography Segments
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Other
Asia-Pacific
China
Japan
India
South Korea
Others
RoW
South America
Middle East
Africa
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10325506 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
